

# Curriculum Vitae

## **Seit 2020**

Geschäftsführender Gesellschafter, Mit-Gründer und Chefarzt am Mental Health Institute Berlin

## **2020-2020**

Chefarzt an der Klinik Pacelliallee in Berlin-Dahlem

## **2019-2020**

Privatambulanz an der Klinik Pacelliallee in Berlin-Dahlem

## **2018-2019**

Gründungs-Chefarzt und Ärztlicher Direktor der Privatklinik Blumenburg

## **2012-2018**

Chefarzt, Dr. Fontheim – Mentale Gesundheit, Liebenburg;  
Volle Weiterbildungsermächtigung für Psychiatrie und Psychotherapie (48 Monate)

## **2009-2012**

Direktor, Experimentelle Medizin der Neurowissenschaften bei Johnson&Johnson in Beerse / Belgien

## **2007-2009**

Mitglied des Exzellenzclusters „Languages of Emotion“ der Freien Universität Berlin

## **2006-2009**

Universitätsprofessor (W2) für „Klinische Psychiatrie“ und Geschäftsführender Oberarzt an der Charité Berlin

## **2005**

Habilitation zum Thema „genetische Assoziationsstudien bei Alkoholabhängigkeit“ an der Charité Berlin; seither Hochschullehrer an der Charité Berlin

## **2001-2006**

Oberarzt an der Klinik für Psychiatrie und Psychotherapie am Universitätsklinikum Benjamin Franklin / FU Berlin (Campus Benjamin Franklin der Charité - Universitätsmedizin Berlin)

## **1998-1999**

Assistenzarzt an der Klinik für Neurologie, Universitätsklinik Mainz

## **1996-1997**

Klinische Forschergruppe an der Psychiatrischen Klinik der Universität Mainz zum Thema:  
„GABA-Benzodiazepin-Rezeptor-Komplex“

## **1994-2001**

Weiterbildungsassistent an der Psychiatrischen Klinik der Universität Mainz mit Erlangung des Titels „Facharzt für Psychiatrie und Psychotherapie“

## **1991-1994**

Promotion am Physiologischen Institut der Universität Heidelberg mit dem Titel:  
„Untersuchungen ATP-abhängiger Kaliumkanäle in glatten Muskelzellen mittels Patch-Clamp-Technik“

## **1992, 1994**

Clerkships an der Yale University (New Haven / USA) und Harvard Medical School (Boston / USA)

## **1987-1994**

Medizinstudium an den Universitäten Mainz, Heidelberg und an der Jefferson Medical School (Philadelphia / USA)

## **Mitgliedschaften**

- Verband der leitenden Krankenhausärzte Deutschlands
- Deutsche Gesellschaft für Suchtforschung und Suchttherapie e.V.
- Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN)
- Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (EGNP)
- Deutsche Gesellschaft für Bipolare Störungen (DGBS)
- Berliner Gesellschaft für Psychiatrie und Neurologie (BGPN)
- International Society of Psychoneuroendocrinology (ISPNE)
- European College of Neuropsychopharmacology (ECNP)
- Verein zur Förderung psychisch Kranker e.V. in Liebenburg

## **Wissenschaftliche Gutachtertätigkeit**

- Aging Health
- Annals of General Psychiatry
- British Journal of Medicine
- Case Reports in Psychiatry / CNS Drugs
- Comprehensive Psychiatry
- Deutsche Medizinische Wochenschrift (DMW)
- DNP (Fachbeirat)
- Evidence-Based Complementary and Alternative Medicine
- Frontiers in Oncology
- Frontiers in Psychology
- Future Medicine
- International Clinical Psychopharmacology
- International Journal of Psychiatry in Clinical Practice
- International Journal of Psychiatry in Medicine
- Journal of Addiction and Preventive Medicine
- Journal of Affective Disorders
- Journal of Clinical Psychopharmacology
- Journal of Psychiatry and Neuroscience
- Journal of Psychopharmacology
- Nervenarzt
- Niederländische Regierung
- Nordic Journal of Psychiatry
- Obesity Facts
- Pharmacological Research
- Pharmacopsychiatry
- Phytomedicine
- Planta Medica
- Psychiatria Danubina
- Psychiatry Investigation
- Psychiatry Research
- Psychiatry Research: Neuroimaging
- Psychopharmakotherapie / Schizophrenia Research
- Sucht
- World Journal of Biological Psychiatry

## Wissenschaftliche Veröffentlichungen

### Bücher - Books

- Angheliescu I., Dettling M., Hofer A.: „Moderne Behandlungskonzepte der Negativsymptomatik bei Schizophrenie“, UNI-MED Verlag, Bremen 2020.
- Gründer G., Benkert O.: Psychopharmaka-Entwicklung: Von der Entdeckung bis zur Zulassung“ in “Handbuch der Psychopharmakotherapie”, 2. Auflage, Springer 2011.
- Klein H. E., Pajonk F.-G., Ko-Autor des Buches: "Psychiatrie und Psychotherapie. 1000 kommentierte Prüfungsfragen" (Gebundene Ausgabe). Thieme, Stuttgart, 2006; 2. Auflage 2008; 3. Auflage 2010; 4. Auflage 2018
- Benkert O., Hippus H. (Hrsg.): Ko-Autor des Buches: "Kompendium der Psychiatrischen Pharmakotherapie"; Springer-Verlag, Heidelberg.1998 (1. Auflage), 2000 (2. Auflage), 2000 (überarbeitete und korrigierte 2. Auflage), 2001 (3. Auflage), 2003 (4. Auflage), 2005 (5. Auflage), 2007 (6. Auflage), 2008 (7. Auflage), 2014 (10. Auflage), 2016 (11. Auflage); 2018 (12. Auflage), 2021 (13. Auflage)
- Benkert O. (Hrsg.): Ko-Autor des Buches: "Pocket Guide Psychopharmaka von A bis Z"; Springer-Verlag, Heidelberg. 2010 (1. Auflage), 2015 (3. Auflage), 2017 (4. Auflage), 2019 (5. Auflage), 2021 (6. Auflage)
- Benkert O., Hautzinger M., Graf-Morgenstern M (Hrsg.): Ko-Autor des Buches „Psychopharmakologischer Leitfaden für Psychologen und Psychotherapeuten“, Springer-Verlag Heidelberg, 3. Auflage, 2016
- Offermanns/Rosenthal: Ko-Autor des Buches: "Encyclopedia of molecular pharmacology"; 2003, 2. Auflage 2008, 3. Auflage 2021.
- Holsboer/Gründer/Benkert; Ko-Autor des Buches: "Handbuch der Psychopharmakotherapie" (Hrsg.), Springer-Verlag, 2007.
- Rupprecht/Hampel, Ko-Autor des Buches: "Roter Faden Psychiatrie und Psychotherapie"; Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 2006.
- Angheliescu/Regen: "CME Schizophrenie und bipolare Störungen-Behandlung von Mischzuständen bei bipolaren Störungen", 2005, Thieme-Verlag, Stuttgart.
- Bauer/Berghöfer/Adli: Ko-Autor des Buches: "Akute und therapieresistente Depressionen", Springer-Verlag, Heidelberg, 2. Auflage 2005.
- Bauer/Berghöfer/Brakemeier/Adli: Ko-Autor des Buches: "Therapieresistenz bei Depressionen und Bipolaren Störungen", Springer Nature, Indien, 2022.
- Heuser/Angheliescu: Ko-Autor des Buches: "Kognitives Altern und Demenzerkrankungen"; UNI-MED Verlag, Bremen 2003.
- Wetzel H., Szegedi A., Angheliescu I., Härtter S., Hiemke C.: Interaktionen von Clozapin mit anderen Psychopharmaka. Clozapin - Pharmakologie und Klinik eines atypischen Neuroleptikums; Naber D., Müller-Spahn F. (Hrsg.), Springer-Verlag, Heidelberg,1997.
- Kreye VAW., Angheliescu I., Kajioka S., Karle C., Pfründer D.: ATP-Dependent K<sup>+</sup> Channels in Vascular Smooth Muscle. Pharmacological Control of Calcium and Potassium Homeostasis edited by Godfraind T., Mancina G., Abbracchio MP., Aguilar-Bryan L., Govoni S., Kluwer Academic Publishers, Dordrecht, The Netherlands, 1995.

## Peer-reviewed publications (nach Publikationsdatum, in absteigender Reihenfolge)

- Angheliescu IG: Ein interdisziplinäre Aufgabe. DNP 2022; 23 (5):3
- Schulte EC et al. / Angheliescu IG: A novel longitudinal clustering approach to psychopathology across diagnostic entities in the hospital-based PsyCourse study. Schizophr Res. 2022 Jun;244:29-38. doi: 10.1016/j.schres.2022.05.001. Epub 2022 May 11.PMID: 35567871
- Kirchner SK et al. / Angheliescu IG: Medication Adherence in a Cross-Diagnostic Sample of Patients From the Affective-to-Psychotic Spectrum: Results From the PsyCourse Study. Front Psychiatry. 2022 Jan 20;12:713060. doi: 10.3389/fpsy.2021.713060. eCollection 2021.PMID: 35126191
- Smigielski L et al. / Angheliescu IG: Polygenic risk scores across the extended psychosis spectrum. Transl Psychiatry. 2021 Nov 26;11(1):600. doi: 10.1038/s41398-021-01720-0.PMID: 34836939
- Heilbronner U et al. / Angheliescu IG: Interplay between the Genetics of Personality Traits, severe Psychiatric Disorders, and COVID-19 Host Genetics in the Susceptibility to SARS-CoV-2 Infection - ADDENDUM. BJPsych Open. 2021 Nov 18;7(6):e206. doi: 10.1192/bjo.2021.1037.PMID: 34789355
- Heilbronner U et al. / Angheliescu IG: Interplay between the genetics of personality traits, severe psychiatric disorders and COVID-19 host genetics in the susceptibility to SARS-CoV-2 infection. BJPsych Open. 2021 Oct 7;7(6):e188. doi: 10.1192/bjo.2021.1030. eCollection 2021 Nov.PMID: 34659794
- Wendel B et al. / Angheliescu IG: A Genome-Wide Association Study of the Longitudinal Course of Executive Functions. Transl Psychiatry. 2021 Jul 10;11(1):386. doi: 10.1038/s41398-021-01510-8.
- Angheliescu IG, Studer K: Individualisierte Psychopharmakologie. Swiss Arch Neurol Psychiatr Psychother. 2021;172:w03181.
- Angheliescu IG, Burkart M, Frank D: Naturarzneimittel bei innerer Unruhe. Pharm Ztg 2020;165:2702-2708.
- Angheliescu IG: Indikationen für Depotneuroleptika. DNP 2020;21(4): 22-30.
- Dwyer DB et al. / Angheliescu IG: An investigation of psychosis subgroups with prognostic validation and exploration of genetic underpinnings: the PsyCourse study. JAMA Psychiatry 2020 Feb 12. doi: 10.1001/jamapsychiatry.2019.4910. [Epub ahead of print].
- Comes AL et al. / Angheliescu IG: The role of environmental stress and DNA methylation in the longitudinal course of bipolar disorder. Int J Bipolar Disord 2020 Feb 12;8(1):9.
- Ueberberg B et al. / Angheliescu I. Drug-induced liver injury (DILI) in patients with depression treated with antidepressants: a retrospective multicenter study. Pharmacopsychiatry 2020 Mar;53:60-64.
- Kronenberg G, Desai D, Angheliescu I: When two drugs are not better than one: Treating mood symptoms in patients with chronic opioid use. J Affect Disord 2019 Dec 1;259:173-174.
- Comes AL et al. / Angheliescu IG: The genetic relationship between educational attainment and cognitive performance in major psychiatric disorders. Transl Psychiatry 2019 Aug 28;9(1):210.
- Kronenberg G, Desai D, Angheliescu I: Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 2019 Jul;6(7):560.
- Anderson-Schmidt H et al. / Angheliescu IG: The influence of religious activity and polygenic schizophrenia risk on religious delusions in schizophrenia. Schizophr Res 2019 Jan 3, doi: 10.1016
- Budde M et al. / Angheliescu IG: A longitudinal approach to biological psychiatric research: The PsyCourse study. Am J Med Genet B Neuropsychiatr Genet. 2019 Mar; 180(2):89-102.
- Kalman JL et al. / Angheliescu I: Investigating polygenic burden in age at disease onset in bipolar disorder: Findings from an international multicentric study. Bipolar Disord. 2019 Feb 28;21(19):68-75.

- Severus E, Sauer C, Bauer M, Ostacher M, Angheliescu IG. A Novel Study Design to Systematically Explore the Impact of Trial Methodology on Psychopharmacological Treatment Outcome in Patients with Depression. *Pharmacopsychiatry*. 2018 Jul 5. doi: 10.1055/a-0643-4796.
- Angheliescu I, Moschner C: Prazosin for Post-Traumatic Stress Disorder. *N Engl J Med*. 2018 Apr 26;378(17):1648-9. doi: 10.1056/NEJMc1803171.
- Angheliescu IG, Edwards D, Seifritz E, Kasper S: Stress management and the role of *Rhodiola rosea*: a review. *Int J Psychiatry Clin Pract*. 2018 Jan 11:1-11. doi: 10.1080/13651501.2017.1417442
- Wilhelm R, Ahl B, Angheliescu IG: Dextrometorphan-Paroxetine, But Not Dronabinol, Effective for Treatment-Resistant Aggression and Agitation in an Elderly Patient With Lewy Body Dementia. *J Clin Psychopharmacol*. 2017 Dec;37(6):745-747. doi: 10.1097/JCP.0000000000000805.
- Bahari-Javan S. et al. / Angheliescu I. (Co-Author): HDAC1 links early life stress to schizophrenia-like phenotypes. *PNAS Early Edition* 19.05.2017 (<http://www.pnas.org/content/early/2017/05/19/1613842114.full.pdf>)
- Angheliescu I.: "Zombie" Outbreak Caused by Synthetic Cannabinoid. *N Engl J Med*. 2017 Apr 20; 376(16):1597. doi: 10.1056/NEJMc1701936. •
- Angheliescu I.: Inhibitor of Fatty Acid Amide Hydrolase – Learning from Tragic Failures, *N Engl J Med*. 2017 Jan 26; 376(4):392.
- Solmi M, Veronese N, Zaninotto L, van der Loos ML, Gao K, Schaffer A, Reis C, Normann C, Angheliescu IG, Correll CU: Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. *CNS Spectr*. 2016 Oct;21(5):403-418.
- Angheliescu I: Online Intervention for Prevention of Major Depression. *JAMA*. 2016 Aug 23-30;316(8):881. doi: 10.1001/jama.2016.9583.
- Angheliescu I: Methadone for prisoners. *Lancet*. 2016 Jan 16; 387(10015):224-5. doi: 10.1016/S0140-6736(16)00045-3. Epub 2016 Jan 15.
- Kasper S, Angheliescu I, Dienel A: Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep - A randomized, placebo-controlled trial. *Eur Neuropsychopharmacol*. 2015 Nov; 25(11):1960-7. doi: 10.1016/j.euroneuro.2015.07.024.
- Dettling M, Angheliescu I: Housing for Homeless Adults with mental illness. *JAMA*. 2015 Jun 23; 313(24):2493. doi: 10.1001/jama.2015.5745.
- Samara MT, Leucht C, Leeflang MM, Angheliescu IG, Chung YC, Crespo-Facorro B, Elkis H, Hatta K, Giegling I, Kane JM, Kayo M, Lambert M, Lin CH, Möller HJ, Pelayo-Terán JM, Riedel M, Rujescu D, Schimmelmann BG, Serretti A, Correll CU, Leucht S.: Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. *Am J Psychiatry*. 2015 Jun 5:appiajp201514101329.
- Salih H., Angheliescu I., Kezic I., Sinha V., Hoeben E., Van Nueten L., De Smedt H. De Boer P.: Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies. *J Psychopharmacol*. 2015 Mar 3. pii: 0269881115573403
- Dettling M., Angheliescu I.: Psychotropics and risk of violent crime. *Lancet* 2014 Dec 6; S. 384
- Brakemeier EL., Merk A., Wilbertz G., Quante A., Regen F., Bührsch N., van Hall F., Kischkel E., Danker-Hopfe H., Angheliescu I., Heuser I., Kathmann N., Bajbouj M.: Cognitive-behavioral therapy as continuation treatment to sustain response after electroconvulsive therapy in depression: a randomized controlled trial. *Biol. Psychiatry* 2014 Aug 1; S. 194-202.
- Brakemeier EL., Merkl A., Wilbertz G., Quante A., Regen F., Bührsch N., Hall FV., Kischkel E., Angheliescu I., Danker-Hopfe H., Heuser I., Kathmann N., Bajbouj M.: Reply to: Continuation Antidepressant Strategies After Electroconvulsive Therapy: Ultrabrief Pulse Versus Cognitive-Behavioral Therapy. *Biol. Psychiatry* 2014 Jul 9; S. 0006-3223.
- Angheliescu I., Dettling M.: Pregabalin versus pramipexole for restless legs syndrome. *N Engl J Med*. 2014 May 22; 370 (21): 2049-50.
- Angheliescu I., Dettling M.: Variant GADL1 and response to lithium in bipolar I disorder. *N Engl J Med*. 2014 May 8; 370(19): 1859.
- Marder SR., Alphs L., Angheliescu IG., Arango C., Barnes TR. et al.: Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. *Schizophr Res*. 2013 Sep 9(13); S. 0920-996400447-7.

- Zeugmann S., Buehrsch N., Bajbouj M., Heuser I., Angheliescu I., Quante A.: Childhood maltreatment and adult proinflammatory status in patients with major depression. *Psychiatr Danub.* 2013 Sep;25(3):227-35.
- Quante A., Regen F., Schindler F., Volkmer K., Severus E., Urbanek C., Luborzewski A., Roepke S., Angheliescu I.: Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study. *Psychiatr Danub.* 2013 Sep;25(3):214-20.
- Fehr C., Sommerlad D., Sander T., Angheliescu I., Dahmen N., Szegedi A., Mueller C., Zill P., Soyka M., Preuss UW.: Association of VMAT2 gene polymorphisms with alcohol dependence. *J Neural Transm.* 2013 Aug; 120(8): 1161-9.
- Anderson-Schmidt H., Adler L., Aly C., Angheliescu IG., Bauer M. et al.: The "DGPPN-Cohort": a national collaboration initiative by the German Association for Psychiatry and Psychotherapy (DGPPN) for establishing a large-scale cohort of psychiatric patients. *Eur Arch Psychiatry Clin Neurosci.* 2013 Apr 3.
- Angheliescu IG., Janssens L., Kent J., de Boer P., Tritsmans L., Daly EJ., van Nueten L., Schmidt ME.: Does early improvement predict response to the fast-dissociating D(2) receptor antagonist JNJ-37822681 in patients with acute schizophrenia? *Eur Neuropsychopharmacol.* 2013: 1043-50.
- Peth J., Regen F., Bajbouj M., Heuser I., Angheliescu I., Hornung OP.: The influence of daytime napping versus controlled activity on the subjective well-being of patients with major depression. *Psychiatry Res.* 2012 Dec 30; 200(2-3): 368-73.
- Schmidt ME., Kent JM., Daly E., Janssens L., Van Osselaer N., Hüsken G., Angheliescu IG., Van Nueten L.: A double-blind randomized placebo-controlled study with JNJ-37822681, a novel, highly, selective, fast dissociating D receptor antagonist in the treatment of acute exacerbation of schizophrenia. *Eur Neuropsychopharmacol.* 2012 Oct; 22(10):721-33.
- Schmidt M. E., Justine M. Kent, E. D., Janssens L., Van Osselaer N., Hüsken G., Angheliescu IG., Van Nueten L.: A double-blind, randomized, placebo controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D2 receptor antagonist in the treatment of acute exacerbation of schizophrenia. Accepted for publication in *Eur Neuropsychopharm* 2012.
- Zeugmann S., Quante A., Popova-Zeugmann L., Kössler W., Heuser I., Angheliescu I.: Pathways linking early life stress, metabolic syndrome, and the inflammatory marker fibrinogen in depressed inpatients. *Psychiatr Danub.* 2012; 24 (1): 57-65.
- Angheliescu I., Dettling M.: Neuron number in children with autism. *JAMA.* 2012 Feb 22; 307(8): 783; author reply 783-4. No abstract available.
- Stassen H., Angheliescu I.G., Angst J., Böker H., Lötscher K., Rujescu D., Szegedi A., Scharfetter C.: Predicting response to psychopharmacological treatment: survey of recent results. *Pharmacopsychiatry.* 2011 Sep; 44(6): 263-72. Epub 2011 Sep 28.
- Roepke S., Luborzewski A., Schindler F., Quante A., Angheliescu I., Heuser I., Bajbouj M.: Stimulus pulse-frequency-dependent efficacy and cognitive adverse effects of ultrabrief-pulse electroconvulsive therapy in patients with major depression. *J ECT.* 2011 Jun; 27 (2): 109-13.
- Quante A., Zeugmann S., Regen F., Engelhardt A., Angheliescu I.G.: Psychopharmacological treatment status in outpatients with bipolar disorder: a clinical survey in Germany. *Psychiatry Investig.* 2010 Sep; 7 (3): 155-62.
- Zeugmann S., Quante A., Heuser I., Schwarzer R., Angheliescu I.: Inflammatory markers in depressed patients with and without the metabolic syndrome. *J Clin Psych* 2010 Aug; 71(8): 1007-16.
- Reese J., Kraschewski A., Angheliescu I., Winterer G., Schmidt L. G., Gallinat J., Rüschemendorf F., Rommelspacher H., Wernicke C.: Haplotypes of dopamine and serotonin transporter genes are associated with antisocial personality disorder in alcoholics. *Psychiatr Genet.* 2010 Aug; 20(4): 140-52.
- Quante A., Zeugmann S., Luborzewski A., Schommer N., Langosch J., Born C., Angheliescu I., Wolf J.: Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study. *Hum Psychopharmacol.* 2010 Mar; 25 (2): 126-32.
- Angheliescu I.: Omega-3 fatty acids for CHD with depression. *JAMA.* 2010 Mar 3; 303 (9): 836; author reply 836.
- Angheliescu I.: Successful smoking cessation and improvement of negative symptoms with varenicline in a stable schizophrenic patient. *J Neuropsychiatry Clin Neurosci* 2009 Winter; 21 (1): 102-3.

- Angheliescu I., Dierkes W., Volz H.P., Loeschmann P.A., Schmitt A.B.: Therapeutic effects of venlafaxine extended release for patients with depressive and anxiety disorders in the German outpatient setting - results of 2 observational studies including 8500 patients. *Fortschr Neurol Psychiatr.* 2009 Nov; 77(11): 646-54.
- Kraschewski A., Reese J., Angheliescu I., Winterer G., Schmidt L.G., Gallinat J., Finckh U., Rommelspacher H., Wernicke C.: Association of the dopamine D2 receptor gene with alcohol dependence: haplotypes and subgroups of alcoholics as key factors for understanding receptor function. *Pharmacogenet Genomics.* 2009 Jul; 19 (7): 513-27.
- Quante A., van Hall F., Angheliescu I.: Psychopharmacological combination therapy in bipolar disorder, *Fortschr Neurol Psychiatr.* 2009 May; 77 (5): 252-62.
- Angheliescu I., Dettling M.: Are new drugs for schizophrenia better than old ones? *Lancet* 2009 Apr 11; 373 (9671): 1249.
- Dettling M., Angheliescu I.G.: Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. *N Engl J Med* 2009 Feb 26; 360 (9): 931.
- Ziegenhorn A.A., Roepke S., Schommer N.C., Merkl A., Danker-Hopfe H., Perschel F.H., Heuser I., Angheliescu I.G., Lammers C.H.: Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder. *J Clin Psychopharmacol* 2009; 29: 170-3.
- Hornung O.P., Regen F., Dorn H., Angheliescu I., Kathmann N., Schredl M., Danker-Hopfe H., Heuser I.: The effects of donepezil on the sleep EEG of healthy older adults: implications for sleep related memory consolidation. *Pharmacopsychiatry*, 2009; 42 (1): 9-13.
- Angheliescu I., Klawe C., Benkert O.: Update pharmacotherapy 2009. *DNP* 2009 (1/09): 52-54.
- Angheliescu I., Klawe C., Singer P., Fehr C., Hiemke C., Quante A., Regen F., Dahmen N., Szegedi A.: Low novelty seeking and high self directedness scores in alcohol-dependent patients without comorbid psychiatric disorders homozygous for the A10 allele of the dopamine transporter gene. *World J Biol Psych* 2009 Jan 30: 1-8.
- Dettling M., Opgen-Rhein C., Angheliescu I.: Escitalopram, problem-solving therapy, and poststroke depression. *JAMA* 2008 Oct 15; 300 (15): 1757.
- Roepke S., Merkl A., Dams A., Ziegenhorn A., Angheliescu I.G., Heuser I., Lammers C.H.: Preliminary Evidence of Improvement of Depressive Symptoms but not Impulsivity in Cluster B Personality Disorder Patients treated with Quetiapine: an Open Label Trial. *Pharmacopsychiatry*, 2008 Sep; 41(5): 176-81.
- Angheliescu I.: Placeboresponse bei Depression. *DNP*, 2008 (8/08): 34-36.
- Hornung O.P., Regen F., Warnstedt C., Angheliescu I., Danker-Hopfe H., Heuser I., Lammers C.H.: Declarative and preceudural memory consolidation during sleep in patients with borderline personality disorder. *J Psychiatr Res* 2008 Jul; 42(8): 653-8.
- Angheliescu I., Regen F.: SSRI tapering and suicidal ideation in the TORDIA study for treatment of depressed adolescents. *JAMA* 2008 Jun 18; 299 (23): 2745-6.
- Quante A., Röpke S., Merkl A., Angheliescu I., Lammers C.H.: Psychopharmacologic Treatment of Personality Disorders. *Fortschr Neurol Psychiatr.* 2008 Mar; 76(3): 139-48.
- Stiglmayr C.E., Ebner-Priemer U.W., Bretz J., Behm R., Mohse M., Lammers C.H., Angheliescu I.G., Schmahl C., Schlotz W., Kleindienst N., Bohus M.: Dissociative symptoms are positively related to stress in borderline personality disorder. *Acta Psychiatr Scand.* 2008 Feb; 117 (2): 139-47.
- Angheliescu I.: Unipolare depressive Störungen-Therapieerfolg stabilisieren und Rezidive verhindern. *DNP* 2008; 5: 43-55.
- Bernard F., Angheliescu I.: Fluoxetin plus Quetiapin - die Kombination wirkt nicht additiv. *Info Neurologie/Psychiatrie* 2008; 10 (12): 12.
- Schindler F., Angheliescu I., Regen F., Jockers-Scherübl M.: Improvement in refractory obsessive compulsive disorder with dronabinol. *Am J Psychiatry* 2008; 165 (4): 536-7.
- Dettling M., Angheliescu I., Bajbouj M.: Electroconvulsive therapy for depression. *N Engl J Med* 2008; 358 (6): 645.
- Schulte-Herbrüggen O., Angheliescu I.: Selective serotonin reuptake inhibitors and osteoporosis: pathomechanism and clinical relevance remain to be established. *Arch Int Med* 2008; 168 (1): 110.
- Angheliescu I., Regen F.: Anxiety and depression in cancer patients, part 2: drug treatment. *Ärztliches Journal Onkologie* 2008; 3: 1-3.

- Hornung O.P., Regen F., Danker-Hopfe H., Heuser I., Angheliescu I.: Sleep-related memory consolidation in depression: an emerging field of research. *Depress Anxiety*. 2008; 25(12): E 163-5.
- Luborzewski A., Schubert F., Seifert F., Danker-Hopfe H., Brakemeier E.L., Schlattmann P., Angheliescu I., Colla M., Bajbouj M.: Metabolic alterations in the dorsolateral prefrontal cortex after treatment with high-frequency repetitive transcranial magnetic stimulation in patients with unipolar major depression. *J Psychiatr Res* 2007 Oct; 41(7): 606-15.
- Quante A., Zeugmann S., Bajbouj M., Angheliescu I.: Clozapine in medication- and electroconvulsive therapy-resistant, depressed inpatients: a case series. *J Clin Psychopharmacol* 2007; 27(6): 715-7.
- Angheliescu I., Heuser I.: Acetylcholinesterase inhibitors for dementia- an update. *MMW Fortschr Med* 2007; 21 (Suppl 2): 76-8.
- Kasper S., Angheliescu I.G., Szegedi A., Dienel A., Kieser M.: Placebo controlled continuation treatment with hypericum extract WS 5570 after recovery from a mild or moderate depressive episode. *Wien Med Wochenschr* 2007; 157: 362-6.
- Schindler F., Angheliescu I.G.: Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. *Int Clin Psychopharmacol*. 2007; 22 (3): 179-82.
- Merkl A., Regen F., Schindler F., Krüger S., Angheliescu I.: Mixed episodes in bipolar disorder: a review. *Fortschr Neurol Psychiatr* 2006; Oct 10.
- Fehr C., Sander T., Tadic A., Lenzen K.P., Angheliescu I., Klawe C., Dahmen N., Schmidt L.G., Szegedi A.: Confirmation of association of the GABRA2 gene with alcohol dependence by subtype-specific analysis. *Psychiatr Genet* 2006; 16 (1): 9-17.
- Fehr C., Sander T., Tadic A., Lenzen K.P., Angheliescu I., Klawe C., Dahmen N., Schmidt L.G., Szegedi A.: Confirmation of association of the GABRA2 gene with alcohol dependence by subtype-specific analysis. *Psychiatr Genet* 2006; 16 (1): 9-17.
- Dettling M., Opgen-Rhein C., Angheliescu I.: Homocysteine lowering and cognitive performance. *N Engl J Med* 2006; 13: 1390.
- Wolf J., Fiedler U., Angheliescu I.: Schwertfeger N. Manic switch in a patient with treatment-resistant bipolar depression treated with modafinil. *J Clin Psychiatry* 2006; 67 (11): 1817.
- Dettling M., Opgen-Rhein C., Quante A., Angheliescu I.: Fluoxetine for treatment of anorexia nervosa. *JAMA* 2006; 296 (20): 2439-40.
- Dettling M., Opgen-Rhein C., Angheliescu IG.: Homocysteine lowering and cognitive performance. *N Engl J Med*. 2006; 355 (13): 1390.
- Kasper S., Angheliescu IG., Szegedi A., Dienel A., Kieser M.: Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial. *BMC Med* 2006; 23 (4): 4-14.
- Luborzewski A., Regen F., Schindler F., Angheliescu I.: Modafinil-induced reversible hyperkinetic nondystonic movement disorder in a patient with major depressive disorder. *J Neuropsychiatry Clin Neurosci* 2006; 18 (2): 248-9.
- Dettling M., Angheliescu I.: Antipsychotic drugs and schizophrenia. *N Engl J Med* 2006; 354 (3): 298-300.
- Lieb K., Angheliescu I.: Neue Antidepressiva-Entwicklungen: Gibt es Wege aus der Innovationskrise? *InfoNeurologie&Psychiatrie* 2006; 8 (2): 38-43.
- Angheliescu IG., Kohnen R., Szegedi A., Klement S., Kieser M.: Comparison of Hypericum Extract WS(R) 5570 and Paroxetine in Ongoing Treatment after Recovery from an Episode of Moderate to Severe Depression: Results from a Randomized Multicenter Study. *Pharmacopsychiatry* 2006 39 (6): 213-9.
- Angheliescu I., Klawe C.: Innovationen in der Pharmakotherapie 2005: Neuzulassungen und Zulassungserweiterungen. *DNP* 2005; 12:4 8-51.
- Scheurich A., Müller M.J., Angheliescu I., Lörch B., Dreher M., Hautzinger M., Szegedi A.: Reliability and Validity fo the Form 90 interview (Form 90). *Eur Addict Res* 2005; 11: 50-6.
- Regen F., Angheliescu I.: The pharmacotherapy of affective disorders in diabetic patients. *Med Welt* 2005; 56: 184-8.
- Angheliescu I., Urbanek C.: Tadalafil in patient with treatment-resistant depression and antidepressant polypharmacy. *J Clin Psychopharmacol* 2005; 25 (2): 191-2.
- Angheliescu I., Jänen B., Schindler F., Lammers CH.: Worsening of Borderline Symptoms under Reboxetine Treatment. *J Neuropsychiatry Clin Neurosci* 2005; 17 (4): 559-60.



- Tadic A., Dahmen N., Szegedi A., Rujescu D., Giegling I., Koller G., Angheliescu I., Fehr C., Klawe C., Preuss U.W., Sander T., Toliat M.R., Singer P., Bondy B., Soyka M.: Polymorphisms in the NMDA subunit 2B are not associated with alcohol dependence and alcohol withdrawal-induced seizures and delirium tremens. *Eur Arch Psychiatry Clin Neurosci* 2005; 255 (2): 129-35.
- Angheliescu I., Müller-Forell W.: Bilateral exophthalmos plus depression - not always endocrine ophthalmopathy. *J Neuropsychiatry Clin Neurosci* 2005; 17 (3): 427.
- Angheliescu I.-G.: Senior is without energy and has memory problems. Depression or beginning dementia? *MMW Fortschr Med* 2005; 147 (35-36): 16.
- Angheliescu I.-G., Regen F.: St. John's wort in depression. The question is not whether it is effective but how do we use it. *MMW Fortschr Med* 2005; 147 (29-30): 17.
- Angheliescu I., Klawe C., Fehr C., Singer P., Schleicher A., Himmerich H., Hiemke C., Dahmen N., Szegedi A.: The TPH intron 7 A218C polymorphism and TCI dimension scores in alcohol-dependent patients: hints to nonspecific psychopathology. *Addict Behav* 2005; 30 (6): 1135-43.
- Regen F., Bajbouj M., Angheliescu I., Folkerts H.: For and against: broader indication of electroconvulsive therapy. *Psychiatr Prax* 2005; 32 (8): 378-80.
- Regen F., Merkl A., Heuser I., Dettling M., Angheliescu I.: Diabetes and depression. *Dtsch Med Wochenschr* 2005; 130 (17): 1097-102.
- Scheurich A., Müller M.J., Szegedi A., Angheliescu I., Klawe C., Lörch B., Kappis B., Bialonski H.-G., Hautzinger M.: Neuropsychological status of alcohol-dependent patients: increased performance through goal-setting instructions. *Alcohol Alcohol* 2004; 39: 119-125.
- Roepke S., Treudler R., Angheliescu I., Orfanos C. E., Tebbe B.: Patch test positive hypersensitivity syndrome to valproic acid in a psychiatric patient. *Am J Psychiatry* 2004; 161 (3): 579.
- Himmerich H., Müller M.J., Angheliescu I., Klawe C., Wetzel H., Szegedi A.: Beziehungen von biologischen Markern exzessiven Alkoholkonsums. *Suchtmed* 2001; 2: 67-72. *German J Psychiatry* 2004; 7: 14-9.
- Himmerich H., Müller M. J., Angheliescu I., Klawe C., Scheurich A., Szegedi A.: Antisocial personality disorder and its correlate in the Michigan. *Alcoholism Screening Test. Germ J Psychiatry* 2004; 7: 14-9.
- Angheliescu I.: Kognitives Altern und Demenz - Viele Faktoren drosseln den Denkprozeß. *NeuroTransmitter* 2004; 4: 56-58.
- Wetzel H., Szegedi A., Scheurich A., Lörch B., Singer P., Schläfke D., Sittlinger H., Wobrock T., Müller M.J., Angheliescu I. and Hautzinger M. for the NeVeR Study Group: Combination treatment with nefazodone and cognitive-behavioral therapy for relapse prevention of alcohol dependent men: a randomized controlled study. *J Clin Psychiatry* 2004; 65 (10): 1406-1413.
- Angheliescu I.: Kognitives Altern und Demenz - MCI - Schmale Kluft zwischen Physiologie und Pathologie. *NeuroTransmitter* 2004; 4: 60-63.
- Angheliescu I., Klawe C.: Neuerungen in der Pharmakotherapie in 2004; Neuzulassungen und Zulassungserweiterungen. *DNP* 2004; 12: 52-56.
- Angheliescu I., Wolf J.: Aripiprazole in ziprasidone-induced hyperprolactinemia. *J Clin Psychiatry* 2004; 65: 1286-7.
- Schumann G., Rujescu D., Szegedi A., Singer P., Wiemann S., Wellek S., Giegling I., Klawe C., Angheliescu I., Heinz A., Spanagel R., Mann K., Henn F. A., Dahmen N.: No association of alcohol dependence with a NMDA-receptor 2B gene variant. *Mol Psychiatry* 2003; 8: 11-2.
- Himmerich H., Szegedi A., Klawe C., Angheliescu I., Müller M. J.: Distigmine bromide induced acute psychotic disorder in a patient with multiple sclerosis. *Eur Psychiatry* 2003; 18: 318-9.
- Schumann G., Rujescu D., Kissling C., Soyka M., Dahmen N., Preuss U.W., Wieman S., Müller A., Wellek S., Lascorz J., Bondy B., Giegling I., Angheliescu I., Cowen M.S., Poustka A., Spanagel R., Mann K., Henn F.A., Szegedi A.: Analysis of genetic variations of Protein Tyrosine Kinase fyn and their association with alcohol dependence in two independent cohorts. *Biol Psychiatry* 2003; 54: 1422-6.
- Lange-Asschenfeldt C., Müller M.J., Szegedi A., Angheliescu I., Klawe C., Wetzel H.: Symptom-triggered versus standard chlormethiazole treatment of inpatient alcohol withdrawal: clinical implications from a chart analysis. *Eur Addict Res* 2003; 9: 1-7.
- Szegedi A., Müller Matthias J., Angheliescu I., Klawe C., Kohlen R., Benkert O.: Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. *J Clin Psychiatry* 2003; 4: 413-20.

- Angheliescu I., Klawe C.: Innovationen in der Pharmakotherapie 2003/2004. DNP 2003; 12: 38-44.
- Angheliescu I., Klawe C., Dahmen N.: Venlafaxine in mirtazapine-induced agranulocytosis. J Clin Psychiatry 2002; 63: 838.
- Angheliescu I., Klawe C., Szegedi A.: Add-on combination treatment of obese patients with different eating behavior. J Clin Psychopharmacol 2002; 22: 521-4.
- Schlösser R., Gründer G., Angheliescu I., Hillert A., Ewald-Gründer S., Hiemke C., Benkert O.: Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 2002; 46: 33-40.
- Himmerich H., Müller M.J., Angheliescu I., Klawe C., Szegedi A.: Erythrozytenzahl und Vitamin B2-Serumspiegel korrelieren bei männlichen alkoholkranken Patienten. Suchtmed 2002; 4: 152-156.
- Himmerich H., Müller M.J., Angheliescu I., Klawe C., Scheurich A., Szegedi A.: Dimensionen des Michigan Alcoholism Screening Tests (MAST): Faktorenanalytische Ergebnisse einer deutschen Version. Suchtmed 2002; 3: 205-212.
- Dahmen N., Müller M. J., Germeyer S., Rujescu D., Angheliescu I., Hiemke C., Wetzel H.: Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients. Schizophrenia Research 2001; 49: 223-9.
- Gencik M., Dahmen N., Wiczorek S., Kasten M., Bierbrauer J., Angheliescu I., Szegedi A., Meneczes-Säcker A. M., Epplen J. T.: A prepro-orexin gene polymorphism is associated with narcolepsy. Neurology 2001; 56: 115-7.
- Kuhl V., Angheliescu I., Vogt T.: Intravenöse Immunglobulin- und Prednisolon-Behandlung bei kryoglobulinämischer Polyneuropathie. Nervenarzt 2001; 72: 445-448.
- Fehr C., Schleicher A., A. Szegedi, Angheliescu I., Klawe C., Hiemke C., Dahmen N.: Serotonergic polymorphisms in patients suffering from alcoholism, anxiety disorders and narcolepsy. Prog Neuropsychopharmacol Biol Psychiat 2001; 25: 965-82.
- Angheliescu I., Germeyer S., Müller M.J., Klawe C., Singer P., Dahmen N., Wetzel H., Himmerich H., Szegedi A.: No association between the DRD2 TAQI A1 allele and earlier age of onset of alcohol dependence according to different specified criteria. Alcohol Clin Exp Res 2001; 25: 805-809.
- Angheliescu I., Klawe C., Himmerich H., Szegedi A.: Topiramate in venlafaxine-induced visual hallucinations in an obese patient with an old posterior cerebral artery infarction. J Clin Psychopharmacol 2001; 21: 462-464.
- Angheliescu I., Klawe C., Bartenstein P., Szegedi A.: Normal PET after long-term repeated electroconvulsive therapy. Am J Psychiatry 2001; 158: 1527.
- Himmerich H., Angheliescu I., Klawe C., Szegedi A.: Vitamin B 12 and hepatic enzyme serum levels correlate in male alcohol-dependent patients. Alcohol Alcohol 2001; 36: 26-8.
- Scheurich A., Müller M. J., Wetzel H., Angheliescu I., Klawe C., Ruppe A., Lörch B., Himmerich H., Heidenreich M., Schmid G., Hautzinger M., Szegedi A.: Reliability and validity of the German version of the European Addiction Severity Index (EuropASI). J Stud Alcohol 2000; 61: 916-9.
- Rujescu D., Giegling I., Dahmen N., Szegedi A., Angheliescu I., Gietl A., Schäfer M., Müller-Siecheneder F., Bondy B., Möller H. J.: Association study of suicidal behavior and affective disorders with a genetic polymorphism in ABCG1, a positional candidate on chromosome 21q22.3. Neuropsychobiology 2000; 1: 22-5.
- Dahmen N., Pauly T., Szegedi A., Wetzel H., Angheliescu I., Ferdinand K., Hiemke C.: Adenylyl cyclase activity is increased in younger, but decreased in older, alcoholic patients after detoxification. Alcohol Alcohol 2000; 35: 249-54.
- Angheliescu I., Klawe C., Benkert O.: Orlistat in the treatment of psychopharmacologically induced weight gain. J Clin Psychopharmacol 2000; 20: 716 – 717.
- Szegedi A., Müller M. J., Himmerich H., Angheliescu I., Wetzel H.: Carbohydrate-deficient transferrin (CDT) and HDL cholesterol (HDL) are highly correlated in male alcohol dependent patients. Alcohol Clin Exp Res 2000; 24: 497-500.
- Himmerich H., Müller M.J., Angheliescu I., Klawe C., Wetzel H., Szegedi A.: Beziehungen von alkoholassoziierten Markern. Suchtmed 2000; 2: 268-269.
- Fehr C., Szegedi A., Angheliescu I., Klawe C., Hiemke C., Dahmen N.: Sex differences in allelic frequencies of the 5-HT2C Cys23Ser polymorphism in psychiatric patients and healthy volunteers: findings from an association study. Psychiatr Genet 2000; 10: 59-65.

- Fehr C., Grintschuk N., Szegedi A., Angheliescu I., Klawe C., Singer P., Hiemke C., Dahmen N.: The HTR1B 861G>C receptor polymorphism among patients suffering from alcoholism, major depression, anxiety disorders and narcolepsy. *Psychiatry Res* 2000; 97: 1-10.
- Gründer G., Wetzel H., Schlösser R., Angheliescu I., Hillert A., Lange K., Hiemke C., Benkert O.: Neuroendocrine response to antipsychotics: effects of drug type and gender. *Biol Psychiatry* 1999; 45: 89-97.
- Mäkelä R., Uusi-Oukari M., Oja S. S., Alho H., Angheliescu I., Klawe C., Lüddens H., Korpi E. R.: Furosemide action on cerebellar GABA(A) receptors in alcohol-sensitive ANT rats. *Alcohol* 1999; 19: 197–205.
- Szegedi A., Angheliescu I., Wiesner J., Schlegel S., Weigmann H., Härtter S., Hiemke C., Wetzel H.: Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. *Pharmacopsychiatry* 1999; 32: 148-53.
- Angheliescu I., Szegedi A., Schlegel S., Weigmann H., Hiemke C., Wetzel H.: Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective clinical trial. *Eur Neuropsychopharmacol* 1998; 8: 315–320.
- Szegedi A., Angheliescu I., Pauly T., Dahmen N., Müller M.J., Wetzel H., Hiemke C.: Activity of the adenylyl cyclase in lymphocytes of male alcoholic patient is state dependent. *Alcohol Clin Exp Res* 1998; 22: 2073–9.
- Wetzel H., Angheliescu I., Szegedi A., Wiesner J., Weigmann H., Härtter S., Hiemke C.: Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. *J Clin Psychopharmacol* 1998; 18: 2-9.
- Pfründer D., Angheliescu I., Kreye V. A.: Intracellular ADP activates ATP-sensitive K<sup>+</sup> channels in vascular smooth muscle cells of the guinea pig portal vein. *Plügers Arch* 1993; 423: 149-51.

### Abstracts and supplements (extract)

- Angheliescu IG, Klement S, Burkart M. Bewertung natürlicher Präparate zur Behandlung innerer Unruhe aus Sicht der Anwender. *Phytotherapiekongress Münster* September 2019.
- Rößner-Ruff V / Angheliescu IG: Geschlechterspezifische Unterschiede bei depressiven Erkrankungen? „Nicht-typische“ Symptome – Ursachen und Einflussfaktoren. Poster presentation at the DGPPN Congress Berlin, 2018.
- Jacobs GE, van Amerongen G, van Gorsel HC, Alvarez-Jimenez R, McAuliffe T, Angheliescu I, Singh J, Fedghin M, Salvadore G, Timmers M, van Gerven J, de Boer P: An exploratory study to investigate the effect of minocycline on depressive symptom relapse after response to ketamine in patients with therapy resistant major depressive disorder (TRD). *J Psychopharmacol* 2015; Abstract supplement to Issue 29, Number 8, August 2015.
- Angheliescu I.: Wirkstoff Lavendelöl: Den Bedürfnissen der Patienten gerecht werden; *MMW* Nr. 18, 2014; Beilage
- K. Lötscher, I.G. Angheliescu, S. Braun, R. Bridler, H. H. Stassen: Polypharmacy in psychiatry: clinical practice versus empirical evidence *European Neuropsychopharmacology*, Vol. 20, Supp. 3, August 2010, Elsevier Verlag, S. 378-379
- Brakemeier EL., Merkl A., Wilbertz G., Quante A., Regen F., Bührsch N., van Hall F., Kischkel E., Danker-Hopfe H., Angheliescu I., Heuser I., Kathmann N., Bajbouj M.: Cognitive-Behavioral Therapy as Continuation Treatment to Sustain Response After Electroconvulsive Therapy in Depression: A Randomized Controlled Trial. *Biol. Psychiatry* 2013; 12: 0006-3223
- Kasper S., Angheliescu I., Schläfke S.: A multi-centre, placebo-controlled, randomised clinical study with Silexan in patients with sub-threshold anxiety. *European Neuropsychopharmacology* Volume 23, Supplement 2, 2013, S. 512 (Poster presented at the 26th ECNP Congress, Barcelona, 5-9 October 2013).
- Kent J., Angheliescu I.G., Kezic I., Daly E., Ceusters M., de Smedt H., van Nueten L., de Boer P.: Safety, Tolerability and Potential Therapeutic Efficacy of a Novel Glutamate Modulator as Adjunctive Treatment in Patients with Schizophrenia 2013.

- de Boer P., Sinha V., Hoeben E., Angheliescu I.G., Kezic I., Daly E., Ceusters M., de Smedt H., van Nueten L., Kent J. M.: Characterization of the Clinical Effect of a Positive Allosteric Modulator of the Metabotropic Glutamate Receptor-2. *Biol Psychiatry* 2013; 73: 319S
- Angheliescu I.G., Kezic I., Van Nueten L., De Boer P.: Esketamine as a Challenge Tool to evaluate the Effect of novel glutamatergic Compounds: Which neuropsychiatric Symptoms are best suited for this purpose? Society of Biological Psychiatry 67th Annual Scientific Convention & Program, May 3-5, 2012, Philadelphia.
- Angheliescu I.G., Janssens L., Kent J., de Boer P., van Osselaer N., Tritsmans L., Daly E. J., van Nueten L.: Early prediction of sustained treatment response with JNJ-37822681, a novel fast dissociating D2 receptor antagonist, compared to olanzapine in schizophrenia. *Biol Psychiatry* 2011; 69: 227S.
- Angheliescu I.G., Janssens L., Kent J., de Boer P., van Osselaer N., Tritsmans L., Daly E.J., Van Nueten L., Schmidt M.E.: Sustained Treatment Response in Schizophrenia to JNJ-37822681, a Novel, Fast- Dissociating D2 Receptor Antagonist, Can be Predicted Within Three Days ”; for the 24th European College of Neuropsychopharmacology (ECNP) Congress, September 3-7, 2011, Paris, France (poster presentation).
- Merkl A., Schneider G.H., Kühn A., Bührsch N., Abbushi A., Kühl K.-P., Angheliescu I., Heuser I., Bajbouj M.: Deep brain stimulation (DBS) of the subgenual cingulate gyrus for treatment-resistant depression (TRD). *Biol Psychiatry* 2010; 67: 190S.
- Luborzewski A., Merkl A., Quante A., Schubert F., Angheliescu I., Bajbouj M.: MR-Spectroscopy of the dorsolateral prefrontal cortex and anterior cingulum of patients with major depression: comparison with healthy controls and follow-up after a 4-week naturalistic treatment period. *Biol Psychiatry* 2010; 67: 466S.
- Zeugmann S., Quante A., Bührsch N., Heuser I., Angheliescu I.: Childhood maltreatment and adult inflammation in patients with major depression. *Biol Psychiatry* 2010; 67: 790S.
- de Boer P., Angheliescu I.-G., van Iersel T., Schmidt M., Palumbo J.M., van Nueten L.: Fast off-rate dopamine D2 receptor antagonists are well tolerated by healthy subjects despite high levels of central dopamine D2 receptor occupancy. *Biol Psychiatry* 2010; 67: 899S.
- de Boer P., Angheliescu I.-G., van Iersel T., Moolenaar M., Schmidt M., Palumbo J. M., van Nueten L.: Increases in cerebrospinal fluid glycine levels are not associated with psychomotor functioning in healthy subjects following administration of an inhibitor of the glycine reuptake transporter-1. *Biol Psychiatry* 2010; 67: 900S.
- Lötscher K., Angheliescu I.G., Braun S., Bridler R., Stassen H.H.: Polypharmacy in psychiatry: clinical practice versus empirical evidence. *Eur Neuropsychopharmacol* 2010; 20: S378.
- Schmidt M., Janssens L., Kent J., Angheliescu I., Hüsken G., Sinha V., Mannaert E.: Efficacy and safety of JNJ 37822681, a fast dissociating D2 receptor antagonist, in the treatment of schizophrenia. *Eur Neuropsychopharmacol* 2010; 20: S484.
- Angheliescu I.G., Szegedi A.: Translational research in schizophrenia. *Nervenarzt* 2010 (DGPPN congress).
- Kasper S., Angheliescu I.G., Dienel A.: Efficacy of Silexan (WS 1265) in patients with restlessness and sleep disturbances. *Nervenarzt* 2010 (DGPPN congress).
- Buehrsch N.C., Swoboda U., Quante A., Zeugmann S., Bajbouj M., Angheliescu I., Heuser I.: Cortisol awakening reaction in depressed patients with and without early life stress. Presented at the 40th Annual ISPNE Conference in San Francisco on July 23-26, 2009.
- Schipke C., Angheliescu I., Regen F., Heuser I., Peters O.: Antidepressants act on glia cells: Calcium responses of astrocytes to citalopram and fluoxetine in the mouse brain. *Pharmacopsychiatry* 2009; 42 DOI: 10.1055/s-0029-1240216.
- Quante A., Luborzewski A., Bührsch N.C., Langosch J., Zeugmann S., Born C., Angheliescu I., Wolf J.: Aripirazole as adjunct to a mood stabilizer and citalopram in bipolar depression: A randomized, placebo-controlled study *Pharmacopsychiatry* 2009; 42 DOI: 10.1055/s-0029-1240202.
- Bührsch N.C., Swoboda U., Quante A., Zeugmann S., Bajbouj M., Angheliescu I., Heuser I.: 1. Cortisol awakening reaction in depressed patients with and without early life stress. *Pharmacopsychiatry* 2009; 42. DOI: 10.1055/s-0029-1240094.
- van Hall F., Zahn C., Schommer N., Angheliescu I., Heuser I., Bajbouj M. rTMS as add-on to escitalopram: a way to enhance antidepressant response? A randomized, placebo controlled trial. *Pharmacopsychiatry* 2009; 42 DOI: 10.1055/s-0029-1240239.

- Merkl A., Schneider G.H., Kühn A., Bührsch N.C., Angheliescu I., Heuser I., Bajbouj M.: Deep brain stimulation of the anterior subgenual cingulate (Cg 25) in treatment-resistant depression. *Pharmacopsychiatry* 2009; 42 DOI: 10.1055/s-0029-1240173.
- Zeugmann S., Quante A., Marx N., König W., Heuser I., Schwarzer R., Angheliescu I.: 2008-06-04 Impact of the metabolic syndrome on inflammatory biomarkers in inpatients with major depression. *Biological Psychiatry*, Vol.63, number: 7S, p. 216S. Presented at the 63rd annual scientific convention and program of the Society of Biological Psychiatry, May 1-3, 2008, Washington, DC, USA.
- Zeugmann S., Quante A., Schröder C., Angheliescu I., Jordan J.: Effects of modern antidepressants with different mode of action on cardiovascular parameters in patients with major depressive disorder and response to treatment. *European Neuropsychopharmacology*, 2007, Vol.17, Supplement 3, p.S155. Presented at the 9th ECNP Regional Meeting, Sofia, Bulgaria, 27-29 April 2007.
- Zeugmann S., Angheliescu I., Schwarzer R.: Das metabolische Syndrom, aber nicht die Depression selbst beeinflusst Zytokin-Level bei depressiven vollstationär behandelten Patienten. Presented at the DGPPN Kongress 2007, 21.-24. Nov.2007, Berlin, Germany
- Bajbouj M., Luborzewski A., Jakob F., Brakemeier E.-L., Angheliescu I., Heuser I., Seifert F., Schubert F.: Metabolic interaction of metabolites in dorsolateral prefrontal cortex, motor cortex and occipital cortex- A 3 T magnetic resonance spectroscopy study. *Biol Psychiatry* 2007; 61:1S-266S 67S.
- Zeugmann S., Quante A., Schröder C., Angheliescu I., Jordan J.: Effects of modern antidepressants with different mode of action on cardiovascular parameters in patients with major depressive disorder and response to treatment. Presented at the 6th International Forum on Mood and Anxiety Disorders, Vienna, Austria, 29 November-01 December 2006.
- Zeugmann S., Schindler F., Bernard F., Angheliescu I.: Comparing the efficacy of a depression-specific group cognitive behaviour therapy and disorder unspecific group therapy for inpatients with major depressive disorder. *European Archives of Psychiatry and Clinical Neuroscience*, 2006, Vol. 256, Supplement 2 p.II 47. Presented at the 9th Congress of the German Society for Biological Psychiatry, 12-14 October 2006, Munich, Germany.
- Angheliescu I., Dienel A., Kieser M.: Hypericum extract WS 5570 is at least equally effective and better tolerated than paroxetine in moderate to severe depression. *WFSBP-Congress*, Vienna, 30.6.2005.
- Angheliescu I.: Metabolisches Syndrom unter verschiedenen Psychopharmaka. *Nervenarzt* 2004, Suppl.2: S252.
- Angheliescu I., Müller M.J., Klawe C., Singer P., Kasten M., Dahmen N. : (2003) Narcolepsy: increased leptin concentrations and BMIs. 58th Annual Convention and Scientific Program of the Society of Biological Psychiatry, May 14-17, 2003, published in "Biological Psychiatry"
- Angheliescu I.: (2003) New antiepileptic drugs (AED) and atypical antipsychotics (AAP) as mood stabilizers. *AGNP-Congress 2003*, published in "Pharmacopsychiatry".
- Schindler F., Angheliescu I.: The NSAID rofecoxib reduces subjective cognitive impairment associated with ECT. *AGNP-Congress 2003*, published in "Pharmacopsychiatry".
- Angheliescu, I.: Therapeutische Aspekte neuer Antidepressiva. *Arch Pharm Pharm Med Chem* 335: S29.
- Roepke S., Bajbouj M., Lehmann A., Urbanek C., Schindler F., Angheliescu I., Neuhaus A., Szegedi A.: (2003) Determination of predictors of twelve treatments (four weeks) outcome of titrated moderately suprathreshold (low dose) right unilateral electroconvulsive therapy in depression: a two year retrospective analysis. *AGNP-Congress 2003*, published in "Pharmacopsychiatry".
- Angheliescu I., Klawe C., Szegedi A.: (2002) Add-on combination and maintenance treatment: case series of obese patients with different eating behavior. 57th Annual Convention and Scientific Program of the Society of Biological Psychiatry, May 16-18, 2002, published in "Biological Psychiatry".
- Angheliescu I., Wetzel H., Müller M.J., Klawe C., Szegedi A., Gründer G., Schlösser R., Hiemke C.: (2002) Dopaminergic system in schizophrenia and alcohol dependence: the apomorphine challenge test. 57th Annual Convention and Scientific Program of the Society of Biological Psychiatry, May 16-18, 2002, published in "Biological Psychiatry".

- Klawe C., Angheliescu I., Schreckenberger M. : Diclofenac-induzierte musikalische Pseudohalluzinationen mit Minderperfusion des linken Thalamus im 99m-Tc-Bicisat-SPECT. Kongress 2001, Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, Berlin 22.11.2001.
- Angheliescu I., Klawe C., Singer P., Germeyer S., Szegedi A.: Association of MAST scores with the Taq A1 polymorphism. World Psychiatric Association, International Congress 2001, Madrid, Spain, September 30 – October 4, 2001.
- Klawe C., Lörch B., Wollmerstedt N., Schmitt H.G., Scheurich A., Angheliescu I., Szegedi A., Hautzinger M.: Aufmerksamkeitsprozesse bei alkoholabhängigen Patienten unter Cue-exposure. Neuropsychologie-Meeting, Mainz, 13.9.2001-12-18.
- Scheurich A., Müller M.J., Klawe C., Angheliescu I., Szegedi A.: Der neuropsychologische Status von alkoholabhängigen Patienten nach der Entgiftung: Funktionale und motivationale Defizite? Neuropsychologie-Meeting, Mainz, 13.9.2001-12-18.
- Angheliescu I., Klawe C., Benkert O. : Additive Kombinationsbehandlung von adipösen Patienten mit unterschiedlichem Essverhalten. Seminar für Biologische Psychiatrie, Oberlech, 18. – 24.3.2001.
- Angheliescu I., Klawe C., Singer P., Germeyer S., Szegedi A.: Association of the TAQ A1 polymorphism with MAST scores. *Pharmacopsychiatry* 2001; 34: 163.
- Klawe C., Angheliescu I., Singer P., Schanz B.: Prospective study of inpatient violence in a German psychiatric teaching hospital: incidence, patient characteristics and quantification with Staff Observed Aggression Scale (SOAS). *Pharmacopsychiatry* 2001; 34: 106.
- Klawe C., Angheliescu I., Himmerich H., Röhrich J., Szegedi A.: A case of possible N-bezylpiperazine induced persisting perception disorder and description of initial intoxication syndrome. *Pharmacopsychiatry* 2001; 34: 183.
- Szegedi A., Lörch B., Angheliescu I., Klawe C., Scheurich A., Ruppe A., Wetzel H., Hautzinger M.: Cue reactivity as a predictor of response to cue exposure treatment: Results from the NeVeR study. *Pharmacopsychiatry* 2001; 34: 203.
- Klawe C., Angheliescu I., Singer P., Fehr C., Germeyer S., Schleicher A., Hiemke C., Dahmen N., Szegedi A. : Lower novelty seeking and higher self-directedness scores on TCI in alcohol dependent patients homozygous for the A10 allele of DAT1. *Pharmacopsychiatry* 2001; 34: 183.
- Himmerich H., Angheliescu I., Klawe C., Szegedi A.: Serum levels of vitamin B12 and hepatic enzymes correlate positively in male alcohol dependent patients. *Nervenarzt* 2000; Suppl.1: S124.
- Szegedi A., Pauly T., Angheliescu I., Klawe C.J., Dahmen N., Wetzel H., Hiemke C.: (2000): Reduced expression of adenylat cyclase isoforms in lymphocytes of alcohol dependent patients. XXIIInd CINP Congress, 9.–13. Juli 2000 in Brüssel, Belgien. *The International Journal of Neuropsychopharmacology* 3 (Suppl. 1): S. 310.
- Rujescu D., Szegedi A., Angheliescu I., Giegling I., Schäfer M., Müller-Siecheneder F., Bondy B., Möller H.-J., Dahmen N.: (2000) Association study of suicidal behavior and affective disorders with a genetic polymorphism in ABCG1, a positional candiadate on chromosome 21q22.3. *Eur Neuropsychopharmacol* 10, Suppl 3, p S. 259, P.1.102.
- Rujescu D., Szegedi A., Angheliescu I., Giegling I, Schäfer M, Möller HJ, Dahmen N. Unipolar depression and polymorphisms of monoaminoxidases. *American Journal of Medical Genetics* 96: (4) P61 (2000).
- Rujescu D, Giegling I, Szegedi A, Angheliescu I, Schäfer M., Bondy B., Dahmen N. : Suicidal behaviour, affective disorders and a polymorphism in the ABCG1 gene. *American Journal of Medical Genetics* 96: (4) P371 (2000).
- Müller-Siecheneder F., Rujescu D., Szegedi A., Angheliescu I., Gieling I., Gietl A., Schäfer M., Möller H.-J., Dahmen N.: (2000) Association study of affective disorders with genetic polymorphisms of monoamine oxidases. *Eur Neuropsychopharmacol* 10, Suppl 3 p S. 259, No P.1.101.
- Szegedi A., Hevers W., Klawe C.J., Angheliescu I., Dämgen K., Lüddens H.: Dramatically Reduced Sensitivity to GABA without a Change in the Equilibrium Affinity Induced by a Point Mutation in GABAA Receptors. 21th Symposium of AGNP, Nürnberg, October 6–9, 1999. *Pharmacopsychiat.* 32 (1999), S. 213.
- Szegedi A., Meyer T.D., Germeyer S., Angheliescu I., Klawe C.J., Dahmen N., Wetzel H.: Anhedonia and Dopaminergic Polymorphisms in Patients with Alcohol Dependence or Alcohol

Abuse. 21th Symposium of AGNP, Nürnberg, October 6–9, 1999. *Pharmacopsychiat.* 32 (1999), S. 213.

- Fehr C., Wehrmeister K., Szegedi A., Angheliescu I., Wetzel H., Hiemke C., Dahmen N.: Allele Differences Between Men and Women in the 5-HT<sub>2C</sub> Cys23/Ser23 Polymorphism. 21th Symposium of AGNP, Nürnberg, October 6-9, 1999. *Pharmacopsychiat.* 32 (1999), S. 179.
- Szegedi A., Müller M.J., Himmerich H., Angheliescu I., Wetzel H.: Carbohydrate-Deficient Transferrin (CDT) and HDL-Cholesterol (HDL) are Highly Correlated in Male Alcohol Dependent oder Abusing Patients. 21th Symposium of AGNP, Nürnberg, October 6–9, 1999. *Pharmacopsychiat.* 32 (1999), S. 214.
- Szegedi A., Hevers W., Klawe C.J., Angheliescu I., Dämgen K., Lüddens H.: The mechanisms of several recognition sites intersect at a single amino acid to modify channel function. *Journal of Neurochemistry* 73: S. 139 – S. 139; Suppl. S (1999).
- Angheliescu I., Hiemke C., Wetzel H.: Evaluation of the dopaminergic hypothesis in male schizophrenic patients by means of the apomorphine challenge test. *Pharmacopsychiatry* 1999; 32: 112.
- Angheliescu I., Hiemke C., Müller M.J., Klawe C., Szegedi A., Wetzel H. : „Apomorphin-Test“ bei Alkoholabhängigen. Seminar für Biologische Psychiatrie, Oberlech, 17. – 23.3.1999.
- Angheliescu I., Wetzel H., Müller M.J., Szegedi A., Käfer M., Golombek M., Hiemke C.: Evaluation of the dopaminergic hypothesis as a trait marker in male alcohol-dependent patients by the apomorphine challenge test. ISPNE Congress in Trier 1998; published in “Psychoneuroendocrinology”, 1998.
- Fehr C., Schleicher A., Szegedi A., Angheliescu I., Wetzel H., Mann, K., Germeyer S., Hiemke C., Dahmen N. (1998): 5-HT<sub>2A</sub> receptor polymorphism in patients suffering from alcoholism generalized anxiety disorder and panic disorder. 28th Annual Meeting of the Society of Neuroscience, 7. – 12. November 1998 in Los Angeles, USA. *Soc. Neuroscience Abstracts* 24 (Part 1): 991.
- Dahmen N., Pauly T., Szegedi A., Wetzel H., Angheliescu I., Hiemke C. : Reduced expression of adenylyl cyclase isoforms II and VI in alcoholism. Kongress der Deutschen Gesellschaft für Biologische Psychiatrie, 1. – 3. Oktober 1998 in Jena. *European Archives of Psychiatry and Clinical Neuroscience*, 248 (Suppl. 2): S. 115, No P 159.
- Fehr C., Schleicher A., Szegedi A., Angheliescu I., Wetzel H., Germeyer S., Hiemke C., Dahmen N. (1998): Possible association between 5-HT<sub>2A</sub> receptor polymorphism and alcoholism. Kongress der Deutschen Gesellschaft für Biologische Psychiatrie, 1. – 3. Oktober 1998 in Jena. *European Archives of Psychiatry and Clinical Neuroscience*, 248 (Suppl. 2): S. 132.
- Wetzel H., Szegedi A., Angheliescu I., Pauly T., Dahmen N., Hiemke C.: State dependence of lymphocyte adenylyl cyclase activity in male patients with alcohol dependence. Congress of the German Society for Biological Psychiatry, Jena, Germany 30 September – 2 October 1998. *European Archives of Psychiatry and Clinical Neuroscience*, S. 115.
- Angheliescu I., Germeyer S., Müller M.J., Dahmen N., Wetzel H. and Szegedi A. : DRD2 TAQI A1 allele in alcoholics: no association with earlier age of onset of alcoholism. Congress of the German Society for Biological Psychiatry, Jena, Germany, 30 September – 2 October 1998. *European Archives of Psychiatry and Clinical Neuroscience*, S. 115.
- Szegedi A., Germeyer S., Müller M. J., Angheliescu I., Wetzel H. and Dahmen N. : DRD4 exon III (48bp repeat) polymorphism is associated with novelty seeking and harm avoidance, but not with novelty seeking alone, in alcoholic patients. Congress of the German Society for Biological Psychiatry, Jena, Germany 30 September – 2 October 1998. *European Archives of Psychiatry and Clinical Neuroscience*, S. 132.
- Klawe C. J., Szegedi A., Angheliescu I., Schlegel S., Wiesner J., Weigmann H., Hiemke C. and Wetzel H. : Fluvoxamine Co-Administration to Clozapine in Schizophrenia: Safety and Tolerability Data from a Prospective Clinical Trial. 20th Symposium of AGNP, Nürnberg, October 8 – 11, 1997. *Pharmacopsychiat.* 30 (1997), S. 188.
- Angheliescu I., Szegedi A., Schlegel S., Weigmann W., Hiemke C. and Wetzel H.: Combination Treatment with Clozapine and Paroxetine in Schizophrenia: Safety and Tolerability Data from a Prospective Open Clinical Trial. 20th Symposium of AGNP, Nürnberg, October 8-11, 1997. *Pharmacopsychiat.* 30 (1997), S. 146.

- Hiemke C., Weigmann H., Härtter S., Szegedi A., Angheliescu I., Wetzel H., Benkert O.: Combination of Clozapine and SSRIs in Schizophrenic Patients. Abstracts of the XXth Collegium Internationale Neuro-Psychopharmacologicum Congress Melbourne, Australia, June 23-27, 1996. European Neuropsychopharmacology, S. 217.
- Angheliescu I., Szegedi A., Philipp M., Staab H.-J., Benkert O.: Paroxetine vs. Maprotiline: Effects of Dose Escalation in Non-Responding Depressed Outpatients after 3 Weeks of Treatment. Abstracts 158 19th Symposium of AGNP, Nürnberg, October 4-7, 1995. Pharmacopsychiat. 28 (1995), S. 159.